Liquidia Corporation (LQDA)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Liquidia’s revenue topped consensus in the third fiscal quarter of 2026, based on preliminary results reported November 10, 2026, with revenue up 315% year over year to about $225.3 million (from $54.3 million a year ago) and coming in at $225.3 million versus a $214.2 million estimate (+5.2%, topped). Gross profit was roughly $210.5 million, translating to a gross margin of near 93%. The company generated operating cash flow of about $146.7 million. Looking ahead, consensus for the next period calls for EPS of $0.12 on revenue of $198.3 million.
About Liquidia Corporation
Liquidia Corporation develops and commercializes pulmonary hypertension therapies in the healthcare sector, with a focus on pharmaceutical products for the United States market. Listed on the NASDAQ Capital Market as LQDA, Liquidia generated $158.3 million of revenue in FY2025 from a business centered on treprostinil-based treatments.
Today's Snapshot
LQDA closed 0.6% lower at 56.40, in line with a weaker sector. Shares changed hands at about half of its usual level.
Trading Volume
Below 10d avg (2.2M)
1.2M
vs S&P 500 Today
Moderate Underperformance
-0.32%
Updated: November 18, 2026 at 21:22 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$49.79 - $54.75Buy
- RSI (14)64.57Neutral
- Stochastic %K (14, 3, 3)83.31Sell
- MACD Level (12, 26)3.38Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.